NICO has received a new and updated 510(k) clearance from the US Food and Drug Administration (FDA) for two of its patented brain surgery technologies Myriad and BrainPath.

Myriad it is an automated, multi-functional tool used for precise resection, suction, clot evacuation and tumour removal in neurosurgery, spinal surgery, ENT and otolaryngology.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Approximately 12,000 procedures have been already performed using this technology.

The FDA has updated the recently received clearance for Myriad automated tissue removal technology use in specific neurosurgical indications, to use in primary and secondary brain tumors, vascular abnormalities and malformations, and intraventricular tumors and cysts.

NICO president and chief executive officer Jim Pearson said: “NICO has spent the last five years bringing together key technology elements to enable minimally invasive neurosurgery for subcortical tumours and clots.

“The goal of NICO has always been to create technology that could create less deficits and faster recoveries in brain surgery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The clinical evidence shows this is possible, and we believe that is directly related to finding less disruptive ways to access the brain that were not possible before.

“Approximately 12,000 procedures have been already performed using this technology.”

“And we believe it will revolutionise the intracranial neurosurgical market.”

With initial clearance secured in July 2015, BrainPath access technology is now cleared for use in specific disease conditions such as high grade gliomas and Glioblastoma Multiforme, secondary metastatic tumours, as well as vascular abnormalities like intracerebral hemorrhage.

Myriad and BrainPath can be combined for non-invasive access, automated tumour removal and clot evacuation near critical structures along with collection and preservation of  removed tissue and clots.

Image: NICO Myriad. Photo: courtesy of NICO Corporation.